Axumin

Fluciclovine F-18 · FLUCICLOVINE F-18 221 mCi/mL · Injection, Solution · Intravenous · Blue Earth Diagnostics

NDC 69932-0001-30 · 30 mL in 1 VIAL, MULTI-DOSE · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

GE Healthcare ASNorway
api manufacture
P.e.t.net Houston, LlcUnited States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
Petnet Solutions, Inc.United States
positron emission tomography drug production
The University of Utah DBA Cyclotron Radiochemistry Lab Huntsman Cancer InstituteUnited States
positron emission tomography drug production

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: NDA208054
TE code: —
Approval date: May 27, 2016
Patents / exclusivity: 8 patents, 0 exclusivities

Type	Number / code	Expires
patent	11980674	Apr 23, 2042
patent	10124079	Dec 30, 2035
patent	10716868	Dec 30, 2035
patent	10967077	Dec 30, 2035
patent	10933147	Dec 30, 2035
patent	9387266	Nov 28, 2026
patent	10953112	Nov 28, 2026
patent	10010632	Nov 28, 2026

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Fluciclovine F-18 (Injection, Solution)

Labeler	Strength	First seen	Last seen
Blue Earth Diagnostics	FLUCICLOVINE F-18 221 mCi/mL	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Axumin — NDC 69932-0001-30," retrieved September 3, 2026, https://drugdashboards.com/drug/69932000130.

Free to cite with attribution — see how the data is put together.